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Abstract
Introduction: Venous	thromboembolism	(VTE)	 is	common	in	glioma	patients.	Also,	
spontaneous	intracerebral	hemorrhage	(ICH)	is	frequently	observed	in	subjects	with	
primary	 brain	 tumors.	 Thus,	 the	management	 of	 anticoagulant	 therapy	 for	VTE	 is	
challenging and controversial in these patients. We performed a meta-analysis to 
clarify	the	risk	of	ICH	in	glioma	patients	treated	with	anticoagulant	therapy	for	VTE	
compared	to	glioma	patients	without	VTE.
Materials and Methods: A	systematic	search	of	the	literature	was	conducted	using	
PubMed,	Scopus,	and	EMBASE	databases	between	January	1980	and	January	2019	
without	 language	restrictions.	Summary	statistics	for	 ICH	were	obtained	by	calcu-
lating	the	odds	ratio	(OR)	using	a	random	effects	model,	and	heterogeneity	across	
studies was estimated by the I2	statistic.	The	Newcastle–Ottawa	Scale	was	used	to	
evaluate	the	quality	of	studies.
Results: A	total	of	368	studies	were	initially	identified.	Of	these,	346	were	excluded	
after	title	review.	The	remaining	22	studies	were	reviewed	in	detail.	According	to	the	
PICO	criteria,	15	studies	were	excluded.	Finally,	7	studies	were	included	in	the	meta-
analysis.	The	OR	for	ICH	in	glioma	patients	receiving	therapeutic	anticoagulation	for	
VTE	 versus	 those	who	 did	 not	 receive	 anticoagulation	was	 3.66	 (95%	 confidence	
interval	[CI],	1.84–7.29;	I2	=	31%).
Conclusions: This	meta-analysis	demonstrates	that	anticoagulation	for	VTE	increases	
the	risk	of	ICH	in	subjects	with	malignant	brain	tumors.	Future	studies	are	warranted	
to	fully	understand	the	best	medical	treatment	of	VTE	in	glioma	patients.
K E Y W O R D S
anticoagulation,	brain	cancer,	intracranial	hemorrhage,	meta-analysis,	venous	
thromboembolism
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1  | INTRODUC TION
Venous	thromboembolism	(VTE)	is	common	in	malignant	glioma	pa-
tients. Data suggest that the annual risk of deep vein thrombosis in 
these	patients	can	be	as	high	as	18%	with	a	cumulative	lifetime	risk	
of	approximately	30%	(Brandes	et	al.,	1997;	Drappatz,	Schiff,	Kesari,	
Norden,	&	Wen,	2007).	Also,	spontaneous	intracerebral	hemorrhage	
(ICH)	is	frequently	observed	in	subjects	with	primary	brain	tumors	
(Wakai,	Yamakawa,	Manaka,	&	Takakura,	1982).	Thus,	 in	these	pa-
tients,	 the	management	of	anticoagulant	 therapy	 for	both	preven-
tion	and	treatment	of	VTE	is	complex	and	challenging	(Jo,	Schiff,	&	
Perry,	2014;	Perry	et	al.,	2010;	Porfidia,	Morretti,	&	Landolfi,	2014;	
Senders	et	 al.,	2018).	Few	data	are	available	on	 the	 risk	of	 ICH	 in	
malignant glioma patients who use anticoagulants for the treatment 
of	VTE.
We performed a systematic review and meta-analysis of the 
studies	that	have	evaluated	the	occurrence	of	ICH	in	subjects	with	
malignant	primary	neoplasms	of	the	brain,	who	were	diagnosed	with	
VTE	and,	for	this	reason,	were	treated	with	full-dose	anticoagulant	
therapy	compared	with	malignant	glioma	patients	without	VTE	not	
taking anticoagulant therapy.
2  | METHODS
Data reporting in this review are consistent with the Preferred 
Reporting	 Items	for	Systematic	Reviews	and	Meta-Analyses	state-
ment	(Moher,	Liberati,	Tetzlaff,	&	Altman,	2009).	The	review	ques-
tions	 were	 formulated	 following	 the	 PICO	 criteria	 (Population,	
Intervention,	Comparator,	and	Outcome).	A	systematic	search	of	the	
literature	was	conducted	using	PubMed,	Scopus,	and	EMBASE	da-
tabases	between	January	1980	and	January	2019	without	language	
restrictions. The search strategy used a combination of the following 
keywords:	 glioma,	 glioblastoma,	 oligodendroglioma,	 astrocytoma,	
oligoastrocytoma,	 anticoagulant,	 heparin,	 low-molecular-weight	
heparin,	vitamin	k	antagonist,	direct	oral	anticoagulant	(DOAC),	and	
new oral anticoagulant.
The inclusion criteria were as follows: case–control or cohort 
studies or randomized trials that enrolled patients with primary ma-
lignancy of the central nervous system; a study group treated with 
therapeutic	doses	of	anticoagulants	(including	warfarin,	low-molec-
ular-weight	heparin	or	unfractionated	heparin,	DOACs)	for	VTE	and	
a	control	group	without	VTE	not	 treated	with	anticoagulants;	 and	
available information on the occurrence of intracranial bleeding in 
both groups.
The list of potentially eligible studies was reviewed by two inde-
pendent	reviewers	(A.P.	and	M.G.).	The	reference	lists	of	retrieved	
articles were also scrutinized to identify other publications of interest 
that	were	missed	in	the	first	search	(forward	search).	Disagreements	
between reviewers were resolved by consensus.
Data	 extraction	 was	 performed	 by	 two	 authors	 using	 a	 stan-
dardized	form.	Extracted	information	included	the	following:	study	
design,	sample	size,	baseline	population	characteristic,	type	of	anti-
coagulant,	and	incidence	of	ICH.
The	primary	analysis	was	 conducted	on	 the	 rate	of	 ICH	 in	pa-
tients affected by brain cancers receiving full-dose anticoagulants 
for	VTE	compared	with	those	not	receiving	anticoagulation.
The	Newcastle–Ottawa	 Scale	 (NOS)	was	 used	 to	 evaluate	 the	
quality	of	cohort	 studies	and	case–control	 studies,	acknowledging	
that	a	standardized	quality	rating	for	cohort	studies	is	lacking.	The	
NOS	evaluates	the	selection	of	cohorts	(4	criteria),	comparability	of	
cohorts	(1	criterion)	and	assessment	of	outcomes	(3	criteria)	and,	for	
case–control	studies,	the	selection	of	cases	and	control	(4	criteria),	
comparability	of	cases	and	controls	(1	criterion),	and	assessment	of	
exposure	(3	criteria)	(Wells	et	al.,	2009).
Institutional	 review	 board	 approval	 was	 not	 required	 in	 our	
Institution for a systematic review and a meta-analysis.
2.1 | Statistical analysis
Data of the study populations were reported as per individual stud-
ies.	 The	 number	 of	 patients	who	 experienced	 and	did	 not	 experi-
ence	ICH	was	extracted	both	in	the	anticoagulant	and	in	the	control	
group.	A	random	effect	model	using	inverse	variance	weighting	was	
used to summarize the data. The heterogeneity of pooled data was 
estimated by calculating the Q and I2	statistics,	and	it	was	regarded	
as significant when p < .05 or I2 ≥50%.	Review	Manager	version	5.3	
(Nordic	Cochrane	Centre,	The	Cochrane	Collaboration,	Copenhagen	
2014)	was	used	for	pooling	data.
3  | RESULTS
3.1 | Study selection
A	total	of	368	studies	were	initially	 identified.	Of	these,	346	were	
excluded	after	title	review	because	they	were	not	relevant	for	the	
purpose of the study. The remaining 22 studies were reviewed in 
detail.	 According	 to	 the	 PICO	 criteria,	 15	 studies	 were	 excluded.	
In	 particular,	 eight	 studies	were	 excluded	 because	 no	 comparison	
group	was	available	 (Altschuler,	Moosa,	Selker,	&	Vertosick,	1990;	
Carney	et	 al.,	 2019;	Chaichana	et	 al.,	 2013;	Nghiemphu,	Green,	&	
Pope,	 2008;	 Quevedo,	 Buckner,	 Schmidt,	 Dinapoli,	 &	 O'Fallon,	
1994;	Robins	et	al.,	2008;	Schmidt,	Faul,	Dichgans,	&	Weller,	2012;	
Simanek,	Vormittag,	&	Hassler,	2007),	three	studies	were	excluded	
for	a	different	intervention	(Perry	et	al.,	2009,	2010;	Senders	et	al.,	
2018)	(prophylactic	doses	of	anticoagulant	drugs),	and	four	studies	
were	excluded	because	the	outcome	ICH	was	not	available	(Brandes	
et	 al.,	 1997;	 Chang	 et	 al.,	 2005;	 Edwin	 et	 al.,	 2016;	 Zincircioglu	
et	al.,	2012).	Finally,	7	studies	were	included	in	the	meta-analysis	(Al	
Megren,	De	Wit,	Al	Qahtani,	Le	Gal,	&	Carrier,	2017;	Choucair,	Silver,	
&	Levin,	1987;	Khoury	et	al.,	2016;	Mantia	et	al.,	2017;	Norden	et	al.,	
2012;	Pan,	Tsai,	&	Mitchell,	2009;	Ruff	&	Posner,	1983)	(Figure	1).
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3.2 | Study characteristics
The characteristics of studies included in the meta-analysis are 
shown	in	Table	1.	All	the	included	studies	were	retrospective	(5	co-
hort	studies	and	2	case–control	studies),	and	the	indication	for	anti-
coagulant	use	was	always	acute	VTE.
3.3 | Quality assessment
Overall,	the	quality	of	the	included	studies	was	considered	low-to-
moderate. The risk of bias mainly deals with the comparability of 
cohorts	and	the	outcome	assessment	in	cohort	studies	(Table	2).
3.4 | Risk of ICH
In	a	random	effects	model,	the	pooled	odds	ratio	for	ICH	in	patients	
with a primary malignant brain cancer receiving therapeutic antico-
agulation	 for	 VTE	 versus	 those	without	 anticoagulation	was	 3.66	
(95%	confidence	interval	[CI],	1.84–7.29;	I2	=	31%)	(Figure	2).	In	the	
study	by	Choucair	and	coll.,	odds	ratio	(OR)	calculation	was	not	pos-
sible	because	there	were	no	reported	cases	of	ICH	(Choucair	et	al.,	
1987).	Publication	bias	was	evaluated	by	Funnel	plot,	and	asymmetry	
of	rates	of	hemorrhage	was	not	apparent	(Figure	3).	Due	to	limited	
number	of	studies	included	in	the	meta-analyses,	no	additional	sta-
tistical analysis of bias was performed.
4  | DISCUSSION
The results of this meta-analysis show a significant 3.66-fold in-
creased	 risk	 of	 ICH	 in	 glioma	patients	 treated	with	 full-dose	 anti-
coagulants	for	acute	VTE	as	compared	to	patients	without	VTE	not	
receiving such therapy.
In	certain	clinical	conditions,	the	decision	to	start	or	withhold	
anticoagulant	 therapy	 for	VTE	 is	difficult.	Subjects	with	primary	
malignant	 brain	 tumors	 who	 develop	 VTE	 are	 among	 those	 for	
whom the assessment of the risk–benefit ratio of anticoagulation 
is	 particularly	 complex,	 given	 the	 lack	 of	 solid	 scientific	 data	 to	
drive	 the	 best	 medical	 management.	 A	 previous	 meta-analysis,	
F I G U R E  1  Study	flow	diagram
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which included patients with both cerebral metastases and pri-
mary	malignant	brain	tumors,	found	that	anticoagulant	treatment	
for	VTE	was	not	associated	with	increased	rate	of	ICH	in	patients	
with	cerebral	metastases,	but	was	associated	with	a	threefold	in-
crease	in	the	risk	of	ICH	in	subjects	with	primary	brain	neoplasms	
(Zwicker,	 Karp	 Leaf,	 &	 Carrier,	 2016).	 After	 this	 meta-analysis,	
other two studies have been published and are included in the 
present meta-analysis. Ours is the first meta-analysis that is spe-
cifically limited to patients with primary malignant brain cancer.
The	risk	of	ICH	is	different	between	the	various	studies	included	
in	our	meta-analysis.	For	instance,	in	the	study	by	Al	Megren	et	al.	
(2017),	among	70	glioma	patients	treated	with	full-dose	anticoagu-
lant	therapy,	there	were	11	ICH	(15.7%),	compared	to	2	ICH	(2.4%)	
in	glioma	patients	who	were	not	taking	anticoagulants.	In	this	study,	
the	OR	 for	 ICH	 in	 treated	 versus	 untreated	 patients	 was	 7.5.	 On	
the	other	hand,	 in	the	study	by	Mantia	and	coll.,	 the	authors	have	
distinguished	between	ICHs	of	different	severity,	from	trace	radio-
logic evidence of blood products to overt hemorrhage with mass 
effect	(Mantia	et	al.,	2017).	In	this	study,	any	bleeding	that	occurred	
within	4	weeks	after	surgery	was	excluded	from	analysis.	ICHs	that	
measured	more	than	1	ml	were	classified	as	measurable,	while	hem-
orrhages	 that	 were	more	 than	 10	ml	 in	 volume,	 required	 surgical	
intervention,	 or	were	 associated	with	 clinical	 symptoms	were	 de-
fined	as	major.	When	all	hemorrhages	were	considered	as	a	whole,	
their	1-year	incidence	was	28.1%	in	subjects	receiving	anticoagulant	
therapy	 and	13.6%	 in	 controls.	When	only	measurable	 ICHs	were	
considered,	their	1-year	incidence	was	18.8%	in	the	anticoagulation	
group	and	7.8%	in	the	control	group.	Finally,	when	only	major	ICHs	
TA B L E  2  Study	quality	assessment	(Newcastle–Ottawa	Scale)
Author (year
Cohort studies
Selection Comparability Outcome
Ruff	and	Posner	(1983) ★★★ / ★
Choucair	et	al.	(1987) ★★★ / ★
Pan	et	al.	(2009) ★★★ / ★★
Norden	et	al.	(2012) ★★★ / ★
Khoury	et	al.	(2016) ★★★ ★★ ★★
 
Case–control studies
Selection Comparability Exposure
Mantia	et	al.	(2017) ★★★ ★★ ★★★
Al	Megren	et	al.	(2017) ★★★ ★★ ★★★
F I G U R E  2  Forest	plot	and	pooled	estimate	of	odds	ratio	(OR)	of	intracranial	hemorrhage	in	glioma	patients	receiving	therapeutic	
anticoagulation	for	VTE.	CI,	confidence	interval;	VTE,	venous	thromboembolism
F I G U R E  3  Funnel	plot	of	standard	error	(SE)	of	studies	included	
in	the	meta-analysis.	OR,	odds	ratio
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were	 taken	 into	 consideration,	 the	 1-year	 incidence	was	 14.7%	 in	
subjects	receiving	anticoagulation	versus	2.5%	in	subjects	that	were	
not	on	anticoagulant	therapy	(HR	3.37).	The	study	of	Pan	and	coll.	
included	 subjects	who	have	had	 recent	 surgery	 (Pan	et	 al.,	 2009).	
Of	146	subjects,	41	(28%)	developed	VTE,	25	(17%)	where	treated	
with	full-dose	anticoagulant	and	3	(2%)	developed	ICH.	Norden	and	
coll. studied brain cancer patients treated with bevacizumab and 
receiving	anticoagulant	 therapy	 for	VTE	 (Norden	et	al.,	2012)	ver-
sus	a	control	group	of	non-VTE	patients	treated	with	bevacizumab	
alone.	Bevacizumab	 is	a	humanized	monoclonal	antibody	direct	 to	
vascular endothelial growth factor approved for the treatment of 
glioblastoma. The use of this drug has been associated both with an 
increased	risk	of	VTE	and	bleeding.	The	authors	showed	a	total	of	14	
cerebral	hemorrhages,	respectively,	7	in	patients	treated	with	anti-
coagulants	and	7	in	untreated	patients.	In	this	study,	data	regarding	
brain surgery are not available.
Some	studies	report	that	the	median	survival	is	similar	between	
glioma	patients	with	VTE	who	develop	and	do	not	develop	ICH	(Al	
Megren	et	al.,	2017;	Khoury	et	al.,	2016).	In	another	study,	the	me-
dian survival was similar among patients receiving and not receiv-
ing	 anticoagulation,	 although	 the	 diagnosis	 of	 ICH	while	 receiving	
anticoagulants was associated with a significantly shorter survival 
(Mantia	et	al.,	2017).
A	potential	treatment,	that	 is	alternative	to	anticoagulation	in	
patients	with	a	brain	tumor	and	VTE,	is	the	placement	of	an	inferior	
vena	cava	(IVC)	filter.	However,	this	procedure	has	been	associated	
with	a	high	rate	of	complications	including	malposition,	thrombo-
sis,	and	pulmonary	embolism	(Zwicker	et	al.,	2016).	 In	one	study,	
about	 60%	of	 patients	with	 brain	 tumors	 treated	with	 IVC	 filter	
developed	complications	related	to	the	filter,	including	a	high	rate	
of	pulmonary	embolism	and	 thrombosis	of	 the	 filter	 (45%)	 (Levin	
et	 al.,	 1993).	 In	 a	 recent	 study,	 in	 patients	with	 glioma	 and	VTE	
who	underwent	placement	of	 an	 IVC	 filter,	 the	 rate	of	 recurrent	
VTE	was	30%	with	an	additional	5%	of	mechanical	complications	
regardless of the presence or absence of anticoagulant treatment 
(Edwin	et	al.,	2016).	Thus,	the	use	of	IVC	filters	should	be	carefully	
evaluated	 for	 each	 individual	 patient,	 always	 taking	 into	 consid-
eration	 that,	 for	 primary	 brain	 tumors,	 the	 American	 Society	 of	
Clinical Oncology recommends anticoagulation and does not sup-
port	 the	 routine	 use	 of	 IVC	 filter	 in	 glioma	patient	who	develop	
VTE	7	(Lyman	et	al.,	2013).
Since	DOACs	have	shown	a	significant	 reduction	 in	 the	 risk	of	
intracranial	bleeding	compared	with	vitamin	K	antagonists	both	 in	
patients	with	atrial	fibrillation	and	VTE	(Van	Es,	Coppens,	Schulman,	
Middeldorp,	&	Büller,	2014),	the	idea	that	the	same	advantage	could	
be present also in subjects with brain tumors is fascinating. In one 
study	on	67	subjects	with	primary	brain	tumor	and	VTE,	the	cumula-
tive	incidence	of	any	ICH	was	0%	in	patients	receiving	DOACs	versus	
36.8%	in	those	treated	with	LMWH	with	a	major	ICH	incidence	of	
18.2%	(Carney	et	al.,	2019).	Based	on	this	pivotal	study,	 future	 in-
vestigation	is	warranted	to	establish	the	safety	profile	of	DOACs	in	
subjects with malignant brain tumors.
This	study	has	some	limitations.	First,	it	is	based	on	studies	that	
only	 have	 a	 retrospective	 design.	 Second,	 all	 patients	 included	 in	
the	studies	had	malignant	brain	tumors,	but	the	information	about	
nature,	size,	stage,	and	management	of	the	cancer	(surgery,	chemo-
therapy,	radiation	therapy)	and	additional	risk	factors	for	both	VTE	
and	ICH	are	incomplete	or	absent	across	the	studies.	In	addition,	in	
the	analyzed	studies	patients	with	VTE	were	subjected	to	different	
types of anticoagulants and heterogeneous therapeutic regimens. 
Finally,	the	studies	included	in	the	meta-analysis	did	not	have	a	pro-
tocol-scheduled	imaging	for	the	surveillance	of	ICH,	lacked	a	homog-
enous	definition	of	ICH.
5  | CONCLUSIONS
In	 summary,	 our	 meta-analysis	 suggests	 that	 anticoagulation	 in-
creases	 the	 risk	 of	 ICH	 in	 subjects	 with	 malignant	 brain	 tumors	
and	VTE,	although	 in	some	studies	 ICH	does	not	 influence	overall	
survival.	 In	 the	studies	 included	 in	 this	meta-analysis,	anticoagula-
tion	was	always	based	on	the	use	of	heparin	and/or	vitamin	K	an-
tagonists.	Future	studies	with	DOACs	might	have	an	impact	on	these	
findings.
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